Jezersek B, Cervek J, Rudolf Z, Novaković S
Department of Tumor Biology and Biotherapy, Institute of Oncology, Ljubljana, Slovenia.
Cancer Lett. 1996 Dec 20;110(1-2):137-44. doi: 10.1016/s0304-3835(96)04473-4.
The potential usefulness of MCA, CA 15-3 and CEA in monitoring of breast cancer patients was evaluated in 135 female patients with histologically confirmed breast cancer. The patients were classified into two groups as follows: group of patients with no evidence of disease, NED; and group of patients with progressive disease, PD. In total, 2106 measurements of CEA, CA 15-3, and MCA were performed using an enzyme immunoassay. Serum levels of all three markers in the NED group differed significantly from those of patients with PD. The observed differences in the sensitivity and specificity of CEA, CA 15-3, and MCA tests were not significant. The serum concentrations of a particular marker correlated well with the concentrations of the other two markers, except when CEA was correlated with MCA or CA 15-3 in NED group patients. The elevation of tumor markers preceded by some 7 months the clinical evidence of dissemination, and marker levels reflected at a high percentage the response to therapy in PD patients. Therefore, this clinical study confirmed that MCA, CA 15-3 and also CEA are suited to discriminate between disease and disease-free periods, and also validated the usefulness of markers for treatment response monitoring.
在135例经组织学确诊为乳腺癌的女性患者中，评估了MCA、CA 15 - 3和CEA在监测乳腺癌患者方面的潜在效用。患者被分为以下两组：无疾病证据组（NED）和疾病进展组（PD）。总共使用酶免疫测定法对CEA、CA 15 - 3和MCA进行了2106次测量。NED组中所有三种标志物的血清水平与PD组患者的血清水平有显著差异。CEA、CA 15 - 3和MCA检测在敏感性和特异性方面观察到的差异不显著。除了在NED组患者中CEA与MCA或CA 15 - 3相关时，特定标志物的血清浓度与其他两种标志物的浓度相关性良好。肿瘤标志物的升高比临床播散证据早约7个月，并且标志物水平在很大程度上反映了PD患者对治疗的反应。因此，这项临床研究证实MCA、CA 15 - 3以及CEA适用于区分疾病期和无病期，并且验证了标志物在监测治疗反应方面的效用。
